ONO-1110

ONO-1110 is an endocannabinoid synthesis regulator and indirect cannabinoid receptor modulator which is under development for the treatment of fibromyalgia, generalized anxiety disorder, interstitial cystitis, major depressive disorder…

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

ONO-1110 is an endocannabinoid synthesis regulator and indirect cannabinoid receptor modulator which is under development for the treatment of fibromyalgia, generalized anxiety disorder, interstitial cystitis, major depressive disorder, postherpetic neuralgia, and social phobia. It is taken orally. ONO-1110 is under development by Ono Pharmaceutical in Japan.

As of March 2025, the drug is in phase 2 clinical trials for all indications. Its chemical structure does not yet appear to have been disclosed.

See also

List of investigational antidepressants List of investigational fibromyalgia drugs List of investigational generalized anxiety disorder drugs List of investigational social anxiety disorder drugs

Development Pipeline - Ono Pharmaceutical

Text derived from https://en.wikipedia.org/w/index.php?oldid=1372024936 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

4 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.